Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease

- Extraprostatic extension (EPE+) in a needle biopsy may be more common than previously thought
- Approximately one of six high grade prostate cancers harbor EPE+ in core biopsies
- EPE+ is associated with highly adverse features of prostate cancer, making its reporting obligatory
- More studies are needed to establish the predictive and prognostic value of EPE+ in needle biopsies